On October 28, 2026, amid the burnished glass and limestone atriums of the Cleveland Clinic, a delegation of high federal functionaries assembled to unveil the latest triumph of American statecraft. There stood Dr. Mehmet Oz, the television impresario elevated to administrator of the Centers for Medicare & Medicaid Services; Kyle Diamantas, the attorney serving as acting commissioner of food and drugs; Abe Sutton, the deputy administrator of CMS; and Dr. Tomislav Mihaljevic, the hospital conglomerate’s chief executive officer. They gathered not to announce the expansion of municipal sanitation, nor to rescue the deteriorating clinics of hollowed-out industrial towns, but to inaugurate an administrative apparatus designed to speed three-million-dollar gene therapies from venture-backed laboratories directly onto public balance sheets.
The ceremonial choreography was familiar to anyone acquainted with the court rituals of the late American republic. Whenever the federal government prepares to transfer public resources into private balance sheets, it cloaks the transaction in the language of sacred charity. One day earlier, on October 27, the Department of Health and Human Services, joined by the Food and Drug Administration and CMS, published draft guidance titled Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management under Docket Number FDA-2026-D-11783. The document formalizes a regulatory concept known as the “Individualized Feature Space.”
Behind this sterile bureaucratic nomenclature lies an audacious concession to pharmaceutical capital. Under the new rules, manufacturers of bespoke human genome-editing products need no longer submit each distinct molecular intervention to the rigorous discipline of separate human clinical trials. If a pharmaceutical sponsor secures approval for a platform targeting a monogenic disorder, it may subsequently alter the variable components—specifically, the guide RNA spacer sequences tailored to patient-specific genetic variations—relying solely on laboratory assays and chemistry, manufacturing, and controls data. The state, having long ago surrendered the authority to regulate prices, has now dismantled the traditional machinery of clinical verification.
To complete the circuit, Oz announced that CMS would broaden its Cell and Gene Therapy Access Model. Originally established to negotiate outcomes-based rebate agreements across state Medicaid pools for sickle cell treatments, the program will now encompass customized interventions for ultrarare genetic afflictions. Having relieved biotechnology firms of the burden of proving that each bespoke alteration is safe and effective in living human cohorts, the imperial treasury stepped forward to underwrite the resulting invoices.
The Rhetoric of Pious Exemption
The philosophical architecture supporting this arrangement was articulated with customary imperial piety. “Families confronting rare genetic diseases deserve more treatment options, no matter how few patients share their diagnosis,” declared Robert F. Kennedy, Jr., the secretary of health and human services, in an official statement on October 27. “Under President Trump’s leadership, we are clearing a path for scientists to develop personalized therapies and for patients to access them. We will advance innovation, uphold rigorous safety and effectiveness standards, and put patients with even the rarest diseases at the center of our efforts.”
Diamantas echoed the sentiment with the smooth confidence of a courtier delivering an edict. “For patients with rare genetic diseases, a one-size-fits-all approach to treatment simply does not work and neither should a one-size-fits-all approach to regulation,” he said. The guidance, he insisted, provides commercial sponsors with “the regulatory clarity they need to develop therapies tailored to each patient’s unique genetic makeup, while maintaining the gold standard science that Americans deserve.”
The market understood the transaction with chilling speed. On October 28, following the Cleveland Clinic exhibition, shares of Beam Therapeutics rose 8 percent on Wall Street. Joseph Thome, an analyst at investment firm TD Cowen, remarked to financial reporters that the agency’s guidance created lucrative “plug and play” optionality for commercial gene-editing pipelines. John Evans, the chief executive officer of Beam Therapeutics, took to social media to celebrate the regulatory windfall: “All of this is completely supported by the science of base editing. . . . But it’s still exhilarating to see the FDA crafting such a forward-looking approach.”
What Wall Street celebrated as “plug and play” flexibility was described by Karim Mikhail, the director of the FDA’s Center for Biologics Evaluation and Research, during the National Organization for Rare Disorders Breakthrough Summit in Washington on October 27. Addressing an audience of industry representatives and patient advocates, Mikhail recounted the administrative hurdles that previously obstructed commercial developers. “There was no regulatory pathway for you to take that one gene and apply to the other variants of that gene,” Mikhail said. “Sponsors would have to basically submit a completely new [Biologics License Application] with new efficacy data so it was a very, very heavy burden. . . . Up to now, there was no pathway for individualized gene therapies. . . . It’s going to offer a first-ever pathway for us in the United States . . . to have individualized gene therapy approved for monogene diseases.”
The heavy burden, in short, was the ancient duty of empirical demonstration. By administrative fiat, that burden has been lifted from private enterprise and transferred to the human subjects who receive the infusions and the taxpayers who fund them.
The Precedent of Gilded Philanthropy
The ruling class has always preferred spectacular acts of heroic patronage to the unglamorous obligations of public welfare. In the late nineteenth century, when industrial magnates like Andrew Carnegie and J. Pierpont Morgan looked upon the pestilential tenements of industrial Manhattan, they did not direct their fortunes toward universal sanitation or municipal housing. Instead, they endowed marble hospital pavilions and private surgical theaters, where celebrated physicians performed exotic operations before galleries of admiring peers. The spectacle allowed the Gilded Age oligarchy to pose as benefactors of humanity while the water supplies that sickened millions of working-class families remained untreated.
The modern biotechnology regime operates upon the same aristocratic instinct, updated for the era of securitized finance. The public health crisis of the United States is broad and squalid: maternal mortality rates that disgrace an industrialized nation, diabetes epidemics born of predatory food monopolies, millions denied basic insulin and preventive care because they cannot satisfy insurance deductibles. Yet the federal administrative state devotes its creative energies to manufacturing bespoke genetic elixirs priced between $2.2 million and $3.5 million per single-dose infusion, exemplified by products like Casgevy and Lyfgenia.
The official defense of this regulatory shortcut is not without rhetorical coherence. When a catastrophic illness arises from dozens of distinct genetic point mutations, each afflicting perhaps three or five children across the continent, assembling a randomized, double-blind, placebo-controlled clinical trial of several hundred participants is an arithmetic impossibility. Agency leadership argues that insisting upon traditional clinical phases condemns infants with ultrarare conditions to certain death while life-saving molecular scissors sit idle on laboratory shelves. The regulatory precedent had been advanced in November 2025 by former FDA Commissioner Marty Makary and former CBER Director Vinay Prasad in The New England Journal of Medicine, where they proposed the “Plausible Mechanism Pathway” following the experimental treatment of an infant, KJ Muldoon, who suffered from carbamoyl phosphate synthetase 1 deficiency. On October 15, 2026, the FDA formalized this trajectory with its “Rare Disease Framework Initiative.”
Yet the flaw in the official defense lies in what it conveniently omits. If the state determines that statistical necessity requires dispensing with human trial requirements, it possesses every legal and moral justification to treat the resulting technology as a public utility. The basic genomic insights, the viral vectors, and the underlying CRISPR-Cas mechanisms were developed almost entirely through public subsidies disbursed by the National Institutes of Health. Having paid for the science, the public is now informed by Oz and Diamantas that private corporations must be granted unencumbered monopoly pricing power, absolute freedom from clinical verification for each variant, and an open pipeline to state Medicaid funds.
The Ghost of the Orphan Drug Act
This dynamic is not an accidental administrative aberration; it is the culmination of a four-decade evolution. In 1983, Congress enacted the Orphan Drug Act, promising that federal tax subsidies, research grants, and seven-year windows of market exclusivity would coax reluctant pharmaceutical manufacturers into developing treatments for rare disorders that lacked commercial appeal. It was conceived as a modest civic pact to serve the neglected.
Within two decades, pharmaceutical conglomerates realized that the statute’s definition of rarity was the most lucrative loophole in the history of American commerce. Rather than developing broad treatments for widespread afflictions, corporate laboratories learned to slice common diseases into micro-indications, securing monopoly protections and exorbitant pricing power for therapies that generated tens of billions of dollars in revenue. By the time a corporate titan acquired orphan status for a drug like Humira or Revlimid, the law had been converted from a shelter for the sick into a machine for rent extraction.
The Individualized Feature Space carries this logic to its imperial extreme. By allowing a manufacturer to register a single master biologic application and then swap genetic spacer sequences under laboratory validation alone, the FDA effectively grants pharmaceutical sponsors an open-ended patent estate. It is the pharmaceutical equivalent of an empire granting a favored chartered company the exclusive right to collect customs across an entire coastline, leaving the company free to alter the cargo manifests at will.
The Medicaid Trap
The tragedy of this policy falls upon the public treasuries of the fifty states. Under the expanded Cell and Gene Therapy Access Model, CMS organizes state Medicaid directors into a collective purchasing cartel, negotiating risk-bearing rebate agreements with biopharmaceutical firms. In the administrative imagination of Washington, this risk-pooling constitutes fiscal prudence: if an individualized gene therapy fails to produce its promised clinical endpoint, the private manufacturer returns a portion of the multimillion-dollar fee to the state.
“A medical breakthrough only matters to patients if they can get it,” Oz announced on October 27. “Under President Trump and Secretary Kennedy’s leadership, CMS is working to give Americans with rare diseases, particularly children, a chance at healthier, fuller lives without cost standing in the way. CMS is bringing state Medicaid programs together to negotiate with drug manufacturers to help put life-changing therapies within reach.”
The argument assumes that an impoverished state Medicaid program, operating under statutory balanced-budget amendments, possesses the leverage to negotiate with monopolists holding the sole therapeutic remedy for a dying child. When a manufacturer presents an invoice for $3 million, a rebate promised five years hence provides small comfort to state legislators compelled to balance the ledger in the current fiscal quarter. To pay for a dozen bespoke infusions, a state must quietly restrict dental benefits for low-wage workers, delay maintenance on rural clinics, or purge thousands of working families from public health rolls under the cover of procedural redeterminations.
The public is forced to finance both ends of the monopoly. Working-class taxpayers underwrite the initial university laboratory research through federal taxes; they underwrite the regulatory deregulation through the FDA’s acquiescence; and they underwrite the commercial harvest through state Medicaid budgets. The only element of the process that remains stubbornly privatized is the capital gain, captured by corporate executives and venture funds that trade on the agency’s announcements.
The Imperial Circus
The spectacle staged in Cleveland on October 28 reveals how the ruling class conceives of democratic governance. Faced with structural decay, decaying infrastructure, and a population burdened by predatory health costs, the managers of state and capital assemble to celebrate the miraculous properties of their own administrative exemptions. They speak of compassion and personalized care, but their mechanisms serve to insulate capital from market risk and clinical discipline.
The public comment period for Docket Number FDA-2026-D-11783 will close in late December 2026, after sixty days of formal submission. Over the coming weeks, patient advocacy organizations—frequently subsidized by the very biotechnology companies that stand to gain from the rule—will submit emotional testimonials praising the agency’s boldness. Wall Street analysts will update their financial models, projecting margins on bespoke genetic pipelines that require no subsequent phase 3 trials. In 2027, the CMS contracts will take effect, and the multimillion-dollar billing will commence.
In the decline of imperial states, the sovereign authority invariably confuses the elaboration of privilege with the preservation of the commonwealth. It builds monuments to technological wizardry while the foundations of the republic rot beneath its feet. By turning individualized medicine into an unregulated, publicly underwritten asset class, the court in Washington has demonstrated once again that it views the sick not as citizens entitled to health, but as raw material for financial extraction.